Abstract: The present disclosure relates to methods for treating or preventing heart failure in subjects with elevated left ventricular end systolic volume (LVESV). In particular, the present disclosure related to methods for treating or preventing heart failure in subjects with a LVESV of greater than 70 ml (>70 ml).

Abstract: The present disclosure relates to a microbiome composition for improving muscle strength using a heat-treated fermented culture complex of KM2 Lactiplantibacillus plantarum, wherein the composition according to the present disclosure increased synthesis of myoproteins and showed an effect of inhibiting degradation of myoproteins and animal tests showed an effect of improving muscle strength and increasing leg muscle mass through the increase in grip strength, travel distance, and speed, as well as results in which hamstring muscle strength is improved and muscle mass increases even in a clinical trial. In addition, it was found that the beneficial bacteria increased through an increase in the diversity of intestinal microflora that changed with muscle reduction and improvement in the microflora composition, while the harmful bacteria decreased.

Abstract: An adenovirus that reduces the extent to which neutralizing antibodies bind to the adenovirus has an AB loop that includes a sufficient portion of the amino acid sequence VTINRSA (amino acids 8-14 of SEQ ID NO:2), TYMLSRN (amino acids 8-14 of SEQ ID NO:3), or STMGTSH motif (amino acids 8-14 of SEQ ID NO:4) to reduce binding of neutralizing anti-adenovirus antibodies compared to an adenovirus having a wild-type AB loop. In some cases, another aspect, the adenovirus has an AB loop that includes a sufficient portion of the amino acid sequence VTINRSA (amino acids 8-14 of SEQ ID NO:2), TYMLSRN (amino acids 8-14 of SEQ ID NO:3), or STMGTSH motif (amino acids 8-14 of SEQ ID NO:4) to reduce hemagglutination compared to an adenovirus having a wild-type AB loop. The adenovirus can be used to deliver therapy to a target cell to which the AB loop binds.

Abstract: An application method of an active portion of Ligusticum chuanxiong in preparation of an anti-gout drug is provided, which belongs to the technical field of drugs, relates to an active portion of a traditional Chinese medicine and an application method thereof. An active portion of the Ligusticum chuanxiong for inhibiting xanthine oxidase (XOD, or XO) is an ethyl acetate extract, the ethyl acetate extract mainly includes a small and medium polar lipophilic component, and the small and medium polar lipophilic component is mainly a phthalide compound, and it has been confirmed through experiments that the active portion has an anti-gout effect, in addition, an anti-gout drug and an anti-gout health product containing the active portion of the Ligusticum chuanxiong are provided.

Abstract: The invention belongs to the field of biomedicine technology and discloses the application of Gastrodia elata Blume derived nano-extracellular vesicles in the preparation of drugs for the prevention and/or treatment of subarachnoid hemorrhage (SAH). The Gastrodia elata Blume-derived nano-extracellular vesicles of this invention are obtained from separation of Gastrodia elata Blume by water extraction. The ingredients of this invention are natural, none of toxic side effects and with good biocompatibility and safety. Therefore, this invention has broad application prospects.

Abstract: The disclosure provides pharmaceutical compositions comprising terlipressin having increased concentration with long term storage stability.

Abstract: A method for stimulating hair growth and/or regrowth in a subject is described. The method includes contacting a target region of skin of the subject with an effective amount of a hair growth or regrowth composition comprising a nicotinamide phosphorylribosyltransferase (NAMPT) protein, an active peptide fragment thereof, a NAMPT analog, a vector comprising polynucleotide encoding a NAMPT protein, a NAMPT activator, or a combination thereof.

Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

Abstract: Engineered bacteriophages comprising polynucleotides encoding heterologous proteins under the control of repressible promoters are provided. Also disclosed are processes for producing the engineered bacteriophages, pharmaceutical compositions comprising the engineered bacteriophages and therapeutic and preventive methods using the engineered bacteriophages.

Abstract: The disclosure provides a cytokine engager comprising an antibody that specifically bind human CD8, and wherein the antibody is fused to a cytokine (e.g., IL-2). Compositions and methods of administering the compositions to preferentially expand T cells and treat cancer are also provided.

Abstract: Disclosed are compositions and methods relating to the treatment of a cancer.

Abstract: Provided herein are methods for deactivation of effector cells, such as NK cells, including cells for adoptive cell therapy that are off-the-shelf cells. The deactivated cells may be cryopreserved following deactivation. The deactivated and cell may be expanded and/or activated prior to deactivation, and may or may not comprise a transgene, which may optionally encode a chimeric antigen receptor and/or T cell receptor. In certain embodiments, disclosed are methods for deactivation of NK cells comprising treatment with a kinase inhibitor, for example an mTOR inhibitor and/or a tyrosine kinase inhibitor, for example rapamycin and/or Dasatinib. Also provided herein are deactivated and cryopreserved NK cells, and methods of preparing and/or using the same for treatment of a subject in need thereof, for example treatment of a subject with cancer.

Abstract: This disclosure relates to compositions and uses of caged proteins substituted with a photon decomposing chemical structure wherein the photon decomposing chemical structure is substituted through a linking group to a hydrophilic polymer. In certain embodiments, the caged protein is a proteinaccous agent such as an anticancer agent, cytokine, interleukin, fragment, or fusion thereof.

Abstract: Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and/or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and/or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and/or neurodegenerative diseases.

Abstract: A scraper includes a cover, a first clamping member and a second clamping member. The cover has a connection portion and an insertion protrusion. The first clamping member has a first clamping portion and a first through groove. The second clamping member has a second clamping portion and a second through groove. The connection portion of the cover is detachably connected to one side of the first clamping member opposite to the second clamping member. The insertion protrusion inserts through the first through groove and the second through groove and is detachably coupled to the second clamping member.

Abstract: Razor cartridges are disclosed that include (a) an elongated housing comprising a generally rectangular main portion defining a central open area and having a first width, and a shelf portion extending from the main portion and terminating in a leading edge, the shelf portion having a second width narrower than the first width, (b) a plurality of blades disposed within the open area of the main portion of the housing, and (c) a pair of clips disposed on opposite sides of the open area and configured to secure the blades in the housing, each clip having a pair of legs that wrap around the main portion of the housing outboard of the open area and are bent against a lower surface of the main portion. Shaving systems and methods of shaving are also disclosed.

Abstract: Described herein are examples of a perforating device for perforating a textile material, such as carpet or textile underlayment. In an example, the perforating device includes a multi-blade assembly rotationally driven by a motor. The blade assembly can be coupled to a rotary shaft such that the blades rotate with the shaft. The blades can include alternating teeth and gaps on their outer edges to create a plurality of parallel perforated cuts. Spacers can be positioned between the blades to separate them a predetermined distance. An anvil can be positioned below and adjacent the blade edges such that the teeth of the blades touch or nearly touch the anvil surface. The perforating cuts produce a textile that can be customized in terms of its size and shape at an installation site by hand, and without the need for any specialized tools or equipment.

Abstract: A chainsaw includes a housing and a cutting assembly. The housing includes a central housing, a motor cover arranged obliquely upward at a tail part of the central housing, and a handle housing arranged obliquely downward at the tail part of the central housing, and a hollow structure is arranged between the motor cover and the handle housing. The cutting assembly is arranged on a front side of the central housing, an axis of the cutting assembly is intersected with an axis of the handle housing, and a first intersection thereof is located inside the handle housing.

Abstract: A resin transfer injection apparatus (1) for manufacturing a composite product is provided comprising first and second tools (7, 9), fashioned to at least partially correspond with first and second outer edges of the product, a preform assembly (11), comprising a product preform (12) fashioned to define a shape of the product, fitted between the first and second tools, at least one heater which allows the first and second tools (7, 9) and the preform assembly (11) to reach at least a predefined temperature, at least one spacing device to form a first cavity (19) between the preform assembly (11) and the first tool (7) and a second cavity (21) between the preform assembly (11) and the second tool (9), a tool movement mechanism for closing and opening the first and second tools (7, 9), at least one vacuum pump which establishes a partial vacuum between the first and second tools (7, 9), and a resin injection system which injects a volume of pressurised preheated resin simultaneously into the first and second ca

Abstract: The method for producing a repaired pneumatic tire according to the present disclosure includes: a placement process placing a repair patch, comprising a reinforcement layer consisting of a plurality of reinforcement cords arranged in parallel with each other and surrounded by unvulcanized rubber, on an area to be repaired; and a vulcanization process vulcanizing a tire with the repair patch placed thereon, and in the repaired pneumatic tire, an outer end in the tire radial direction of the repair patch is located on an inner side in the tire width direction than an end of a maximum width belt layer that has the largest width in the tire width direction among the one or more belt layers, and an inner end in the tire radial direction of the repair patch is located on an outer side in the tire radial direction than a tire maximum width position.